**Supplementary Material**

**Table S1:** Characteristics of patients with Acute Toxoplasmic Lymphadenopathy

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

1 0 7/17/2007 7/16/2007 0 cervical

2 30 5/16/2007 5/4/2007 0 cervical, preauricular

3 nr 8/19/2002 8/19/2002 0 generalized LDP

4 36 2/2/2007 2/1/2007 0 cervical

5 53 11/20/2003 11/18/2003 0.1 cervical

6 43 12/8/2007 12/6/2007 0.1 cervical, axillary

7 18 10/31/2002 10/24/2002 0.2 supraclavicular

(L)/submandibular(R

8 47 11/6/2006 11/1/2006 0.2 supraclavicular,

axillary

9 50 11/9/2006 11/1/2006 0.3 occipital,

supraclavicular

10 18 11/8/2001 10/30/2001 0.3 submandibular

11 27 9/28/2002 9/18/2002 0.3 cervical

12 35 1/11/2011 12/30/2010 0.4 cervical

13 nr 10/8/2002 9/25/2002 0.4 submandibular (R)

14 31 7/18/2008 7/6/2008 0.4 cervical (R)

15 31 10/23/2009 10/9/2009 0.5 cervical (posterior, L)

16 24 3/1/2007 2/15/2007 0.5 cervical, axillary

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

17 nr 2/20/2002 2/3/2002 0.6 cervical (L)

18 39 12/18/2002 12/1/2002 0.6 submandibular

19 48 2/9/2004 1/21/2004 0.6 nr

20 31 10/3/2006 9/12/2006 0.7 cervical (R)

21 36 8/1/2001 7/11/2001 0.7 cervical (R)

22 27 12/2/1999 11/12/1999 0.7 nr

23 nr 12/23/1999 11/28/1999 0.8 nr

24 31 12/17/2001 11/23/2001 0.8 cervical, axillary

25 33 12/26/2006 12/1/2006 0.8 cervical

26 47 1/28/2004 1/1/2004 0.9 inguinal (L)

27 32 7/28/1998 6/30/1998 0.9 nr

28 15 9/19/2007 8/20/2007 1 submandibular (L)

29 31 10/31/2006 9/30/2006 1 cervical (L)

30 34 9/30/2011 9/1/2011 1 nr

31 37 11/11/2005 10/10/2005 1 cervical

32 28 1/10/2005 12/10/2004 1 cervical, parotid (L)

33 25 10/6/2006 9/5/2006 1 cervical (posterior, L)

34 24 10/17/2007 9/15/2007 1 cervical and axillary

35 41 11/24/2008 10/24/2008 1 cervical

36 34 3/8/2002 2/7/2002 1 axillary (L)

37 32 5/19/2000 4/19/2000 1 nr

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

38 25 1/17/2001 12/15/2000 1.1 axillary

39 49 1/5/2007 12/1/2006 1.1 cervical (posterior)

40 44 2/16/2006 1/12/2006 1.1 cervical (R )

41 32 4/7/2010 3/1/2010 1.2 cervical (posterior, L)

42 37 10/26/2009 9/20/2009 1.2 cervical (posterior)

43 20 4/9/2003 3/4/2003 1.2 cervical (posterior)

44 46 11/1/2005 9/21/2005 1.3 cervical (L)

45 24 3/10/2005 2/1/2005 1.3 cervical (R )

46 34 4/28/2003 2/15/2003 1.4 nr

47 nr 6/19/1998 5/8/1998 1.4 nr

48 20 9/5/2000 7/20/2000 1.5 nr

49 33 7/9/2007 5/25/2007 1.5 parotid and cervical

50 6 10/12/1998 8/28/1998 1.5 nr

51 29 5/6/2002 3/18/2002 1.6 cervical

52 74 10/4/2007 8/15/2007 1.6 abdominal

53 15 11/2/2004 9/15/2004 1.6 cervical (posterior, L)

54 28 3/10/2004 1/21/2004 1.6 cervical (posterior, L)

55 29 2/21/2007 1/4/2007 1.6 cervical (L)

56 40 5/18/2007 4/1/2007 1.6 cervical, inguinal

57 44 11/9/1998 9/21/1998 1.6 nr

58 nr 7/28/2003 6/7/2003 1.7 cervical (L)

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

59 69 10/5/2002 8/15/2002 1.7 cervical (posterior)

60 44 10/22/2007 9/1/2007 1.7 cervical (R)

61 31 2/7/2001 12/15/2000 1.7 submental,

submandibular(R )

62 49 4/21/2005 3/1/2005 1.7 axillary (R)

63 41 11/23/2004 10/1/2004 1.7 cervical (L)

64 25 2/4/2008 12/12/2007 1.7 cervical

65 48 11/25/2011 10/1/2011 1.8 cervical (posterior, L)

66 29 1/24/2005 12/1/2004 1.8 axillary (L)

67 27 5/8/2002 3/15/2002 1.8 cervical (posterior, L)

68 42 2/28/2008 1/1/2008 1.9 Cervical chain

69 44 11/28/2000 10/1/2000 1.9 cervical (L)

70 51 1/28/2010 12/1/2009 1.9 cervical,

axillary, inguinal

71 56 9/29/2003 8/1/2003 1.9 cervical (R)

72 nr 5/21/1998 3/22/1998 2 nr

73 37 9/14/2009 7/1/2009 2 cervical

74 39 1/29/2002 11/30/2001 2 cervical

75 44 1/30/2006 12/1/2005 2 cervical-mediastinal

76 34 8/12/2005 6/9/2005 2.1 supraclavicular

77 59 12/9/2008 10/7/2008 2.1 pre-auricular (L)

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

78 18 10/11/2007 8/1/2007 2.3 cervical (posterior, L)

79 21 8/4/2009 5/25/2009 2.3 cervical, occipital

80 51 2/10/2003 12/1/2002 2.3 cervical (posterior, L)

81 35 11/10/2006 9/1/2006 2.3 cervical

82 58 10/25/2006 8/9/2006 2.5 axillary

83 49 5/11/2006 2/24/2006 2.6 supraclavicular (L)

84 26 1/24/2006 11/1/2005 2.8 cervical

85 44 11/25/2003 9/1/2003 2.8 parotid

86 21 4/28/2000 2/1/2000 2.9 nr

87 41 10/19/2011 7/22/2011 2.9 cervical (posterior)

88 40 11/30/2005 9/1/2005 3 cervical (posterior, L)

89 17 8/30/2005 6/1/2005 3 submandibular (L)

90 31 8/30/2005 6/1/2005 3 cervical

91 29 2/22/2010 12/1/2009 3 cervical

92 47 4/21/2009 2/1/2009 3 axillary, chest,

abdomen

93 44 3/12/2003 12/11/2002 3 cervical

94 70 7/21/2008 5/1/2008 3 cervical, axillary

95 41 7/31/2006 5/1/2006 3 postauricular

bilateral

96 2 7/5/2007 4/1/2007 3.1 cervical

**ID Age Sample collection LDP onset date Δt LDP location**

**(years) date (months)**

97 34 7/22/2002 4/20/2002 3.1 cervical

98 nr 4/12/2003 12/30/2002 3.4 nr

99 32 3/16/2004 12/1/2003 3.5 cervical (bilateral)

100 36 12/1/2003 8/15/2003 3.5 submandibular

101 14 12/18/2008 9/1/2008 3.6 cervical, axillary

102 20 1/16/2006 9/28/2005 3.6 cervical

103 36 11/22/2006 8/1/2006 3.7 cervical

104 12 12/15/2005 8/20/2005 3.8 occipital (R)

105 35 4/2/2001 12/1/2000 4 cervical (posterior, R)

106 16 1/31/2008 10/1/2007 4 cervical (posterior)

occipital

107 42 2/19/2008 10/15/2007 4.1 cervical (posterior, L)

108 26 10/30/2001 6/23/2001 4.2 cervical (R)

109 16 10/9/2003 6/1/2003 4.3 cervical

110 18 9/12/2008 5/1/2008 4.4 axillary (posterior)

111 31 9/26/2003 5/15/2003 4.4 cervical

112 26 3/12/1998 11/1/1997 4.4 nr

**Abbreviations:** Δt**:** difference in months between the sample collection date and the reported date of lymphadenopathy onset; L: left; LDP: lymphadenopathy; R: right;

**Table S2:** Serologic test results of acute toxoplasmic lymphadenopathy

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

1 0 4096 5.8 5.1 1.6 (Low) 800/1600 (Acute)

2 0 8000 10 4.4 4.5 (Low) 400/200 (Acute)

3 0 256 9.8 7.2 5.1 (Low) nr

4 0 16000 4 11.2 0.4 (Low) >1600/>3200 (Acute)

5 0.1 1024 10.7 1.2 5.7 (Low) 400/100 (Acute)

6 0.1 512 8.8 10 nr <50/<100 (non reactive)

7 0.2 2048 7.7 2.7 1.9 (Low) 1600/800 (Acute)

8 0.2 2048 8.4 11.2 2.2 (Low) >1600/>3200 (Acute)

9 0.3 4096 9.3 7.8 2.6 (Low) 400/800 (Acute)

10 0.3 1024 8.9 2.5 6.2 (Low) nr

11 0.3 32000 9.5 10.2 6.5 (Low) >1600/>3200 (Acute)

12 0.4 2048 6.3 3.9 1.5 (Low) 800/200 (Acute)

13 0.4 16000 8 13.6 4.2 (Low) >1600/1600 (Acute)

14 0.4 8000 8.2 1.1 3.7 (Low) 400/200 (Acute)

15 0.5 512 9.8 4.4 2.6 (Low) 800/200 (Acute)

16 0.5 8000 6.1 11 9.7 (Low) >1600/3200 (Acute)

17 0.6 8000 8.1 24 7 (Low) >1600/>3200 (Acute)

18\* 0.6 128 6.6 0.6 nr <50/<100 (non reactive)

19 0.6 8000 4.3 1.2 7.4 (Low) 1600/400 (Acute)

20 0.7 8000 7.7 11.2 2.7 (Low) >1600/1600 (Acute)

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

21 0.7 1024 7 5.3 2.1 (Low) 800/1600 (Acute)

22 0.7 2048 7 5.7 nr nr

23 0.8 8000 9.9 14.8 nr nr

24 0.8 1024 9.1 10.4 6.7 (Low) nr

25 0.8 8000 7.9 7.3 0.4 (Low) 1600/1600 (Acute)

26 0.9 8000 7.6 7.9 3.4 (Low) >1600/>3200 (Acute)

27 0.9 128 7 2 nr nr

28 1 4096 6.7 10.6 2.6 (Low) 800/800 (Acute)

29 1 4096 9.5 9.5 1.7 (Low) >1600/3200 (Acute)

30 1 1024 4.1 .8 6.4 (Low) 800/200 (Acute)

31 1 8000 5.5 3.9 3.7 (Low) 1600/1600 (Acute)

32 1 1024 8 nr 1.2 (Low) 200/200 (Acute)

33 1 8000 7.8 5 2.9 (Low) >1600/3200 (Acute)

34 1 16000 9.7 6.4 4.3 (Low) 1600/1600 (Acute)

35 1 4096 2.9 1.7 2.9 (Low) 800/1600 (Acute)

36**†** 1 4096 2.5 17 7.8 (Low) nr

37 1 2048 6.1 6.7 nr nr

38 1.1 8000 7.3 28 nr nr

39 1.1 2048 6.4 1.8 1.7 (Low) 800/800 (Acute)

40 1.1 32000 3.5 7.3 14.8 (Low) >1600/>3200 (Acute)

41 1.2 1024 7.2 4.9 1.5 (Low) nr

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

42 1.2 512 7.6 1.7 2.9 (Low) 200/100 (Acute)

43 1.2 32000 8.8 19.3 5.1 (Low) >1600/3200 (Acute)

44 1.3 8000 4.4 nr 3.5 (Low) 1600/1600 (Acute)

45 1.3 8000 9.2 11.2 7.1 (Low) >1600/3200 (Acute)

46 1.4 8000 8.8 6.6 2.6 (Low) >1600/1600 (Acute)

47 1.4 1024 10 5.8 nr nr

48 1.5 2048 8.9 7.4 nr nr

49 1.5 8000 9.9 4.5 4.3 (Low) >1600/1600 (Acute)

50 1.5 8000 8 12.5 nr nr

51 1.6 2048 4.4 1.3 2 (Low) nr

52 1.6 32000 8.5 11.2 2.5 (Low) >1600/3200 (Acute)

53 1.6 32000 7.1 11.2 5.1 (Low) >1600/>3200 (Acute)

54 1.6 32000 10 11.2 1.4 (Low) >1600/1600 (Acute)

55 1.6 8000 8 4.9 2.9 (Low) 1600/3200 (Acute)

56 1.6 1024 9.4 nr 4.3 (Low) 800/400 (Acute)

57 1.6 8000 9.6 6 nr nr

58 1.7 16000 9.4 6.6 4 (Low) >1600/1600 (Acute)

59 1.7 4096 8 0.6 3.9 (Low) >1600/800 (Acute)

60 1.7 32000 7.3 3.1 3.6 (Low) >1600/1600 (Acute)

61 1.7 2048 4.7 5.1 1.7 (Low) nr

62 1.7 8000 8.1 4.9 3.8 (Low) 1600/1600 (Acute)

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

63 1.7 16000 10 nr 3.8 (Low) >1600/3200 (Acute)

64 1.7 16000 8.4 11.2 18.8 (Low) ≥1600/≥3200 (Equivocal)

65 1.8 8000 3.3 7.7 3.8 (Low) >1600/1600 (Acute)

66 1.8 8000 4 5.8 13.2 (Low) >1600/1600 (Acute)

67 1.8 4096 8 5.9 2.2 (Low) >1600/1600 (Acute)

68 1.9 8000 10 1.4 (Low) 1600/800 (Acute)

69 1.9 16000 5.7 5.6 nr >1600/ (Acute)

70 1.9 16000 3.7 6.7 9.3 (Low) >1600/>3200 ( Acute)

71 1.9 8000 4.5 10 11.2 (Low) >1600/>3200 ( Acute)

72 2 32000 7.5 13 nr nr

73 2 8000 4.9 3.6 3.4 (Low) 1600/400 (Acute)

74 2 1024 8.3 12.3 14.8 (Low) nr

75 2 64000 9.2 11.2 6.4 (Low) >1600/>3200 ( Acute)

76 2.1 16000 5.2 nr 3.4 (Low) >1600/1600 (Acute)

77 2.1 8000 7.5 6.9 1.4 (Low) ≥1600/1600 (Acute)

78 2.3 32000 8.1 11.2 5.2 (Low) >1600/>3200 ( Acute)

79 2.3 8000 7.7 3.5 4.1 (Low) 800/800 (Acute)

80**†** 2.3 16000 2.5 3.8 10.3 (Low) >1600/>3200 (Acute)

81 2.3 8000 3.7 11.2 10.8 (Low) 1600/1600 (Acute)

82 2.5 8000 7.6 4.8 4.6 (Low) 800/800 (Acute)

83 2.6 1024 3.9 0.6 7.6 (Low) 400/800 (Acute)

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

84 2.8 32000 5.4 nr 14.2 (Low) >1600/3200 (Acute)

85 2.8 8000 3.4 3.3 7.5 (Low) >1600/≥3200 (Acute)

86 2.9 16000 9.1 9.5 nr nr

87 2.9 8000 6.7 4.6 7.4 (Low) >1600/3200 (Acute)

88 3 8000 7.1 1.6 6.9 (Low) >1600/800 (Acute)

89 3 32000 8.5 nr 3.6 (Low) >1600/3200 (Acute)

90 3 32000 5 11.2 12.4 (Low) >1600/>3200 (Acute)

91 3 2048 7 11 13.5 (Low) >1600/3200 (Acute)

92 3 32000 3 8.3 4 (Low) ≥1600/≥3200 (Acute)

93 3 8000 6.1 2.7 8.5 (Low) >1600/3200 (Acute)

94 3 8000 7.1 11.2 7.4 (Low) 1600/800 (Acute)

95 3 8000 8 11.2 1.9 (Low) >1600/>3200 (Acute)

96 3.1 8000 8.7 9.9 2.6 (Low) 1600/1600 (Acute)

97 3.1 1024 6.4 2.5 6.4 (Low) 800/400 (Acute)

98 3.4 16000 6.2 10.5 11.4 (Low) >1600/>3200 (Acute)

99 3.5 8000 6.6 2.6 6.5 (Low) >1600/1600 (Acute)

100 3.5 1280003.2 4.4 8.1(Low) >1600/>3200 (Acute)

101 3.6 2048 4.1 10.5 7.8 (Low) 1600/1600 (Acute)

102‡ 3.6 8000 5.8 nr 8.6 (Low) 800/3200 (Equivocal)

103 3.7 8000 3 4 4 (Low) >1600/3200 (Acute)

104 3.8 1024 6.3 7.4 5.4 (Low) >1600/1600 (Acute)

**ID Δt IgG IgM IgA Avidity AC/HS**

**(months) (interpretation) (interpretation)**

105 4 8000 3.6 10.1 8.7 (Low) >1600/>3200 (Acute)

106 4 8000 4.9 2.8 3.6 (Low) >1600/3200 (Acute)

107\*\* 4.1 8000 4 2.9 13.8 (Low) 1600/1600 (Acute)

108‡ 4.2 16000 3.6 9.8 23 (Equivocal) 1600/>3200 (Equivocal)

109 4.3 16000 3.4 10 12.6 (Low) >1600/3200 (Acute)

110 4.4 8000 4.2 7.3 9.5 (Low) ≥1600/≥3200 (Acute)

111 4.4 8000 9 2.7 12.2 (Low) >1600/800 (Acute)

112 4.4 8000 6.7 4.9 nr nr **Abbreviations:** Δt= difference in months between sample collection date and date of reported onset of acute lymphadenopathy; nr: not reported

**Footnotes:**

Reference values for serologic test results: Positive IgG Dye test: ≥16 (dilution 1:16), negative <16; positive IgM ELISA: ≥2.0, equivocal 1.7-1.9 and negative ≤1.6; positive IgA ELISA ≥2.1, equivocal 1.5-2.0 and negative ≤1.4; avidity low: ≤20; equivocal 20-30; high: ≥30.Interpretation of the differential agglutination test results available at <http://www.pamf.org/serology/images/achs_grid.html>

\* Although the AC/HS was non-reactive, the serologic test results were still consistent with an acute infection ≤4 months from sample collection date.

† Although the IgM was low positive (2.5), the serologic test results were still consistent with an acute infection ≤4 months from sample collection date.

‡ Although the AC/HS was equivocal, the serologic test results were still consistent with an acute infection ≤4 months from sample collection date.

\*\* Although the avidity was 13.8 (low, but not <10), the serologic test results were still consistent with an acute infection ≤4 months from sample collection date.

Results were similar even if we excluded from the analyses the above 6 cases.